MediWound rises on approval for burn care drug in Japan

KAKEN PHARMACEUTICAL

23/12/2022 15:00

** U.S.-listed shares  MDWD.O  of Israel-based drug
developer MediWound Ltd rise 3.5% to $11.33
    ** Company says its Japanese partner has gained marketing
approval for a burn care drug in Japan
    ** MediWound's partner Kaken Pharmaceutical Co Ltd  4521.T 
has the exclusive right to market and distribute NexoBrid in
Japan
    ** Kaken expects to launch the drug in the summer of 2023
    ** The Japanese Ministry of Health, Labor and Welfare has
granted NexoBrid marketing authorization for non-surgical eschar
removal of deep-partial and full-thickness thermal burns for
adult and pediatric patients
    ** Japan is the first country in the world to approve the
drug for both pediatric and adult populations - MediWound
    ** U.S. FDA has set action date for the drug as on Jan. 1,
2023
    ** Despite session's gains, stock down ~34% YTD
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com))